BCAX (Bicara Therapeutics) FCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCAX Bicara Therapeutics Inc BCAX
14 GF Score
Price $24.28
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics FCF Margin %?

Bicara Therapeutics BCAX +3.10% 14 FCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates BCAX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 955 Biotechnology companies, Bicara Therapeutics ranks worse than 104711.94% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bicara Therapeutics's Free Cash Flow for the three months ended in Jun. 2026 was $-44.27 Mil. Bicara Therapeutics's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Bicara Therapeutics's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, Bicara Therapeutics's current FCF Yield % is -8.40%.

The historical rank and industry rank for Bicara Therapeutics's FCF Margin % or its related term are showing as below:


BCAX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -78.14
* Ranked among companies with meaningful FCF Margin % only.

Bicara Therapeutics FCF Margin % Related Terms

Bicara Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics FCF Margin % Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Margin %
0.00 0.00 0.00 0.00

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCAX vs SLBT, DMRA, TYRA: FCF Margin % Comparison

For the Biotechnology subindustry, Bicara Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's FCF Margin % falls into.


BCAX
14GF Score
Bicara Therapeutics Inc BCAX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bicara Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-107.114/0
= %

Bicara Therapeutics's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-44.266/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Bicara Therapeutics (BCAX) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #999999 out of 955 companies in the Biotechnology industry.
Is Bicara Therapeutics' FCF Margin % too high?
Bicara Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Bicara Therapeutics ranks #999999 out of 955 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bicara Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' FCF Margin % compare to SLBT and DMRA?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #999999 out of 955 companies for FCF Margin %. This places Bicara Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Bicara Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
14GF Score

Get the complete analysis for BCAX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.28
Price